Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis

Double-blinded Placebo-controlled Multicenter Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis

The purpose of this study is to investigate the anti-atherosclerotic effect of long-term anti-inflammatory therapy (Inflaminat) in asymptomatic participants with subclinical atherosclerosis of carotid arteries.

Inclusion Criteria:

• Men aged 40 to 70 years
• Subclinical carotid atherosclerosis detected by B-mode ultrasound (increased intima-media thickness 1000-2000 mcm)
• Arterial normotension or mild arterial hypertension (systolic blood pressure <160 mm Hg, diastolic blood pressure <90 mm Hg)
• Absence of chronic diseases demanding permanent drug administration (more than 2 month per year)

Exclusion Criteria:

• Personal history of stroke or transient ischemic attacks
• Chronic diseases demanding drug administration more than during 2 month per year
• Individual intolerance of Inflaminat or appearance of side effects